CABALETTA BIO INC. - COMMON STOCK

Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases

11 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

06 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference

26 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

10 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

06 Sep 2022 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

29 Aug 2022 13:58:30 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

11 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

18 May 2022 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference

17 May 2022 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

12 May 2022 07:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference

06 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

17 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

01 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

28 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

11 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

10 Jan 2022 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

14 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

09 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

09 Nov 2021 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

01 Nov 2021 07:05:00 By Nasdaq GlobeNewswire